SAN FRANCISCO–(BUSINESS WIRE)–Owkin, an AI company focused on simplifying the complexities of biology, unveiled a groundbreaking agentic infrastructure for biology at the JPM Healthcare Conference 2026. This new framework aims to enhance biomedical research by providing high-quality AI agents to the healthcare ecosystem, further bolstered by a partnership with Anthropic for its Claude for Healthcare and Life Sciences platform.
Founded a decade ago and backed by $300 million in funding, Owkin leverages over ten years of meticulously curated, multimodal patient data sourced from more than 800 hospitals across various geographies. Unlike many competitors that primarily utilize laboratory data, Owkin’s AI agents, trained on real patient information, promise to deliver insights that closely align with the realities of human disease.
The newly launched AI agents can identify biomarkers, interpret complex datasets, and assist in clinical trial decision-making while ensuring patient privacy. The overarching goal is to expedite drug discovery, enhance clinical success rates, and ultimately provide patients with improved treatment options more swiftly.
“This announcement represents a fundamental shift in how the healthcare industry can leverage AI for drug discovery and development,” said Dr. Thomas Clozel, co-founder and CEO of Owkin. “We are now offering specialized agents that can quickly and efficiently assist in research, analysis, and clinical trial decision-making. Our agentic infrastructure acts as a central connector, linking patient data from hospitals, labs, and academic institutions to the pharmaceutical industry through intelligent agents.”
Owkin’s vision extends towards achieving Biological Artificial Super Intelligence (BASI), which refers to AI capable of reasoning across the intricate landscape of biological systems. The company aims to automate scientific research and discovery through its AI scientist, ultimately developing new treatments and diagnostics for patients.
“Our models lay the foundation for AI that can reason about biology at scale, which is what we define as Biological Artificial Super Intelligence,” Clozel continued. “Our platform, domain expertise, and critical partnerships with leading AI companies allow us to make a tangible impact globally within the healthcare ecosystem.”
Among the first agents introduced is Pathology Explorer, part of Owkin’s K Pro community, which is now accessible through Anthropic’s Claude for Healthcare and Life Sciences. This next-generation tool builds on the HIPE (Histo Interpretability Prediction Engine) model, achieving 23.7% better classification accuracy while using five times fewer parameters, significantly reducing computational time from weeks to hours compared to larger models.
The new agentic infrastructure offers several key capabilities for the healthcare industry. First, agents like Pathology Explorer can rapidly identify cell types, gene expression, and biomarkers from digital slides based on curated patient datasets spanning over 800 hospitals. Second, these agents can seamlessly integrate into existing healthcare workflows via API-driven and MCP-compatible technologies, minimizing disruption. Third, continuous improvement of these agents is ensured through lab-in-the-loop testing and the incorporation of new patient data. Lastly, partnerships with eight of the top ten global pharmaceutical companies validate Owkin’s capabilities and strengthen its market position.
Founded to address the intricate challenges in biology, Owkin is on a mission to develop the first Biological Artificial Super Intelligence (BASI). This initiative combines powerful biological large language models, multimodal patient data, and agentic software. Central to this system are Owkin K, an AI copilot, and OwkinZero, a new large language model fine-tuned for biological applications, designed to aid researchers, clinicians, and drug developers in understanding complex biological processes faster and more accurately.
As Owkin continues to advance its technology and partnerships, the implications for drug discovery, clinical trials, and patient care are significant. With a focus on leveraging real-world data and advanced AI capabilities, Owkin is poised to reshape how the healthcare ecosystem approaches research and treatment in the coming years.
See also
Generative AI in Oil & Gas Market Set to Reach $2.3 Billion by 2035, Driven by Automation
Tim Sweeney Clarifies Comments on X’s AI Tool Amid Controversy Over Nonconsensual Images
Google Launches Veo 3.1 with Vertical Video Creation and 4K Upscaling Features
Natera Partners with NVIDIA to Enhance AI Models for Precision Medicine
MCMC Files Lawsuit Against X Corp. and xAI for Grok AI User Safety Violations
